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Daniel Wolff,1 Michael Schleuning,2 Stephanie von Harsdorf,3 Ulrike Bacher,4
Armin Gerbitz,5 Michael Stadler,6 Francis Ayuk,4 Alexander Kiani,7 Rainer Schwerdtfeger,2
Georgia B. Vogelsang,8 Guido Kobbe,9 Martin Gramatzki,10 Anita Lawitschka,11
Mohamad Mohty,12 Steven Z. Pavletic,13 Hildegard Greinix,14 Ernst Holler1Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and
mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is
almost solely based on phase II trials or retrospective analyses. The consensus conference on clinical practice
in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as
well as to provide guidelines for daily clinical practice. Treatment modalities are the use of steroids and
calcineurin inhibitors as well as immunomodulating modalities (photopheresis, mTOR-inhibitors, thalido-
mide, hydroxychloroquine, vitamin A analogs, clofazimine), and cytostatic agents (mycophenolate mofetil,
methotrexate, cyclophosphamide, pentostatin). Recent reports showed some efficacy of rituximab, alemtu-
zumab, and etanercept in selected patients. Moreover, tyrosine kinase inihibitors such as imatinib came into
the field because of their ability to interfere with the platelet-derived growth factor (PDGF-R) pathway in-
volved in fibrosis. An other treatment option is low-dose thoracoabdominal irradiation. Although different
treatment options are available, the ‘‘trial-and-error system’’ remains the only way to identify the drug effec-
tive in the individual patient, and valid biomarkers are eagerly needed to identify the likelihood of response to
a drug in advance. Moreover, the sparse evidence for most treatment entities indicates the urgent need for
systematic evaluation of second-line treatment options in cGVHD.
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Chronic graft-versus-host disease (cGVHD)
remains the leading cause for late morbidity and
mortality after allogeneic hematopoietic stem cell
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Until recently, no valid criteria for the diagnosis and
staging of cGVHD severity were available, which
limits the value of most reported trials on treatment
of cGVHD. Moreover, most of the reported trials
did not use uniform criteria for response and did not
provide details on severity of cGVHD. An additional
problem is the heterogeneity of the patients included
in the analyses, because, for some treatment options,
results in children differ substantially from results
achieved in adults. Although not yet validated in
a prospective fashion, the National Institutes of
Health (NIH) consensus criteria on diagnosis and
staging of cGVHD as well as on treatment response
criteria, reported in 2005, now provide defined
criteria that should improve the validity of future
results on treatment of cGVHD [4-9].
The Consensus Conference on Clinical Practice in
Chronic GVHD held in the fall of 2009 in Regens-
burg, Germany (complete program provided at
www.gvhd.de), aimed to summarize the current avail-
able evidence for second-line treatment and to provide
practical guidelines for the use of treatment modalities.
The presented consensus was based on a review of
published evidence and a survey on the current clinical
practice in transplant centers from Germany, Austria,
and Switzerland, with 31 of 37 centers responding to
the survey. The results of the survey are shown in
Table 1. Moreover, the consensus was circulated
among all centers performing allogeneic HSCT in
Germany, Austria, and Switzerland and was discussed
during the Consensus Conference meetings. The
Consensus Conference was organized under the aus-
pices of theGermanWorkingGroup on BoneMarrow
and Blood Stem Cell Transplantation (DAG-KBT)
and the German Society of Hematology andOncology
(DGHO), the Austrian Stem Cell Transplant Work-
ing Group of the Austrian Society of Hematology
and Oncology, the Swiss Blood Stem Cell Transplan-
tation Group (SBST), and the German-Austrian
Paediatric Working Group on HSCT.
The evaluation of evidence and the subsequent
recommendations were graded according to the
system used by Couriel [10]. Because the evidence of
the majority of treatment options in cGVHD is sparse
and therefore the strength of recommendation falls
into categoryC formost of the therapeutic options, cat-
egory C and evidence III level were further specified as
shown in Tables 2 and 3. Strength of recommendation
and evidence levels were first rated by an expert panel
and subsequently rated by all participants of the
consensus process. Only evidence from the use in
cGVHD was included in the evaluation. We mainly
focus on reported clinical trials and retrospective
analyses. The literature search was performed by the
working group on second-line treatment within the
Consensus conference using the Pubmed database.Only English literature was considered. Abstracts
from the BoneMarrowTransplantationTandemmeet-
ings, the European Bone Marrow Transplantation
meetings, and the American Society of Hematology
meetings were cited but were not included in the
evidence rating.PRINCIPLES OF SECOND-LINE TREATMENT
OF CGVHD
Currently no uniformly accepted definition of
steroid refractory cGVHD is available, and generally
accepted criteria include (1) progression on predni-
sone at 1 mg/kg/day for 2 weeks, (2) stable disease
on $0.5 mg/kg/day of prednisone for 4-8 weeks, and
(3) inability to taper prednisone below 0.5 mg/kg/
day. Treatment duration may vary depending on clin-
ical manifestation (eg, sclerosis requires longer to re-
spond) or toxicity of the agent (eg, shorter duration
in the presence of significant toxicity) [3,7]. Although
different treatment options are available for salvage
therapy of steroid refractory cGVHD, the ‘‘trial-and-
error system’’ remains to date the only way to
identify the drug or drug combination effective in an
individual patient. In principle, initial secondary
treatment should include agents with an adequate
safety profile and well-documented activity like CNI,
extracorporeal photopheresis (ECP), mTOR inhibi-
tors, or mycophenolate mofetil (MMF), whereas
agents with significant side effects should be reserved
to third- or fourth-line treatment. In addition, steroid
sparing should be an important goal of salvage therapy
of cGVHD. Because no predictors of response are yet
available either for single immunosuppressive agents
or combination therapies, most patients receive empir-
ical treatment in daily clinical practice and changes of
therapeutic components in case of lack of response are
performed at the individual clinician’s discretion.
Nevertheless, at time of initiation of secondary or
any further treatment, it is suggested not to change
more than 1 drug at once, because adding several drugs
at once may interfere with identification of the active
component and might lead to prolonged use of inac-
tive components. This does not apply to patients
showing rapid progression of cGVHD, indicating
complete failure of treatment, or the need to withdraw
agents because of toxicity. In the presence of lack of re-
sponse, continuation of at least 1 drug during the
change period is suggested because there is a risk to
end up with a new combination without individual ef-
ficacy, which would leave the patient without effective
immunosuppression.
As in first-line treatment, response to salvage ther-
apy should be assessed after 8-12 weeks. If patients
have progression of cGVHD after 4 weeks, a new
treatment option should be offered. However, patients
should be exposed to therapeutic drug levels for an
Table 1. Results of the Survey on Second-Line Treatment of cGVHD (n 5 30)
Agent
Frequently
Used
Occasionally
Used
Infrequently
Used
Not Used but Regarded as
Treatment Option
Not Regarded
as Treatment Option
No Report
on the Use
Steroids 30
Cyclosporine 22 6 1 1
Tacrolimus 9 8 7 5 1
Photopheresis 13 9 5 1 1 1
Mycophenolat Mofetil 13 9 5 1 1 1
Mycophenolic acid 8 8 3 9 2
Sirolimus 6 6 7 9 1 1
Everolimus 2 9 3 10 2 4
Pentostatin 7 9 7 7
MTX 1 11 4 8 6
Imatinib 6 6 7 7 4
Rituximab 2 13 6 5 1 3
Hydroxychloroquine 3 9 9 9
Clofazimine 2 5 11 12
Thoracoabdominal irradiation 3 8 11 8
Pulse of steroids 5 11 6 2 5 1
Thalidomide 2 2 13 9 4
Azathioprine 1 1 3 10 9 6
Retinoids (Acitretin/Isotretinoine) 1 / 1 0 / 1 7 / 10 12 / 9 10 / 9
Alemtuzumab 1 8 7 9 5
Cyclophosphamide 3 1 9 10 7
Etanercept 2 3 5 10 6 4
MTX indicates methotrexate.
Thirty of 37 transplant centers performing allogeneic HSCTwithin Germany (n5 34), Austria (n5 3), and Switzerland (n5 1) responded to the paper-
based survey on second-line treatment sent via e-mail to representatives of the centers. (One center responded only for first-line treatment and was
excluded from the analysis of second-line treatment.)
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cluding treatment failure. Patients with sclerotic skin
lesions may require substantially longer for responses
(up to 6 months) and treatment may be continued pro-
vided that the patient is closely monitored to recognize
progression of cGVHD. In principle, less immunosup-
pressive therapy is preferable when treating cGVHD,
and thus, agents being identified as ineffective should
be discontinued to avoid side effects. In addition, im-
munosuppression should be reduced as soon as disease
control has been achieved. Thus far, no controlled trial
showed evidence for a beneficial impact of a 3-agent
treatment in first-line therapy [11-13]. Moreover,
a retrospective analysis performed by Mitchell et al.
[14] demonstrated a decline of quality of life in the
presence of multiagent ($2) treatment independent
of severity of cGVHD. These findings, however, do
not necessarily imply that novel immunosuppressive
agents when used in combination would have the
same negative impact on patients’ outcome, as data
in this regard are lacking.
In pediatric patients, systemic steroid therapy can
be deleterious on a growing child. Therefore, addition
of an effective steroid-sparing agent is of crucial
importance for long-term patient outcome. More-
over, topical therapy should be offered in mild cases
both early in the course of cGVHD as well as at the
end of systemic steroid taper. However, topical ste-
roids or topical CNI may lead to significant systemic
drug levels if applied to large areas in small infants,
and thus, their use should be restricted to limited
areas.Althoughnopredictorsof response for a single agent
are yet available, the side effects of specific agents may
limit their use in individual situations. CNI may
be used with caution in case of significant renal
impairment. Thoracoabdominal irradiation as well as
pentostatin may not be given to patients with altered
marrow function [15-17]. mTOR inhibitors had
a lower response rate in patients with low platelets, but
it is unknown whether this is a drug specific effect or
an indicator for cGVHD severity as suggested by the
risk score developed by Akpek et al. and Couriel et al.
[2,18].
From the efficacy standpoint, most of the immuno-
suppressive agents are used for treatment of a broad
spectrum of symptoms of cGVHD. However, some
agents may be more relevant in specific indications be-
cause of a specific mode of action. This is the case in
retinoids, which have been solely applied to sclerotic
skin lesions because of their interference with collagen
synthesis [19]. On the other hand, rituximab may be
considered in immune thrombocytopenia because of
its directed efficacy on B cells [20-22].
Although currently no valid recommendation can
be made for an individual patient, certain combination
of drugs should be avoided because of overlapping tox-
icities. With regard to myelosuppressive capacity, cau-
tion is required when considering thoracoabdominal
irradiation or pentostatin in combination with mTOR
inhibitors [16-18,23]. Moreover, the combination of
mTOR inhibitors with CNIs has been associated with
a significant rate of transplantation-associated microan-
giopathia (TAM) [18,24,25].
Table 2. Strength of Recommendation of Treatment
Strength of
Recommendation Level Definition of Recommendation Level
A Should always be offered
B Should generally be offered
C Evidence for efficacy is insufficient to support for
or against, or evidence might not outweigh
adverse consequences, or cost of the
approach. Optional
C-1 Use in second-line treatment justified
C-2 Use in greater than second-line treatment
justified
C-3 Use because of increased risk profile limited to
specific circumstances
C-4 Experimental, use only in clinical trials or
individual cases
D Moderate evidence for lack of efficacy or for
adverse outcome supports
a recommendation against use. Should
generally not be offered
4 Biol Blood Marrow Transplant 17:1-17, 2011D. Wolff et al.During long-term immunosuppression adequate
monitoring for infectious complications including
screening for viral reactivation and fungal infections
is recommended. Moreover, antifungal prophylaxis
should be considered, especially in patients receiving
a multiagent immunosuppressive regimen or with
a history of invasive fungal infections. Steroids require
monitoring for steroid-induced osteoporosis and
diabetes mellitus. MTOR inhibitors require monitor-
ing of drug levels, signs for TAM, hyperlipidemia, and
blood counts. CNIs require monitoring of drug levels,
arterial blood pressure, and renal function. Moreover,
interactions of certain immunosuppressive agents with
comedications such as azole derivates for antifungal
prophylaxis need to be taken into account.EVALUATING EFFICACYOF TREATMENT
OF CGVHD
In the absence of a single approved immunosup-
pressive agent for salvage therapy of cGVHDTable 3. Quality of Evidence Supporting the Recommenda-
tion
Strength of
Evidence Level Definition of Evidence Level
I Evidence from $1 properly randomized, controlled
trials
II Evidence from >1 well-designed clinical trial without
randomization, from cohort or case-controled
analytic studies (preferable from >1 center) or from
multiple time series, or dramatic results from
uncontrolled experiments
III Evidence from opinions of respected authorities based
on clinical experience, descriptive studies or reports
from expert committies
III – 1 Several reports from retrospective evaluations or small
uncontrolled clinical trials
III – 2 Only 1 report from small uncontrolled clinical trial or
retrospective evaluations
III – 3 Only case reports availableclinicians must resort of trying ‘‘off label’’ drugs. To
be confident about success or failure of each immuno-
suppressive agent applied, the Consensus Conference
advised that a baseline NIH-style comprehensive or-
gan assessment be obtained to serve as a comparison
for follow-up evaluations. In addition, reasons for
treatment changes including progression of symp-
toms, toxic side effects, or patient’s request should be
documented.
TheGerman version of themodified cGVHDstag-
ing form can be downloaded on www.gvhd.de or
www.gvhd.eu. Although most of the organs like oral
and ocular manifestations can be assessed easily and
are frequently reported by the patients, it is of impor-
tance to ask for manifestations infrequently reported
like vaginal manifestations, to prevent prolonged
suffering and irreversible damage. The same applies
for screening of lung manifestations, because mild
involvement can be only detected by evaluation of
lung function. Because moderate lung manifestations
already interfere significantly with quality of life and
physical activity, early intervention seems preferable to
avoid progression to more severe stages taken into ac-
count, that prospective evaluation of this approach has
not been performed yet [26].SECOND-LINE TREATMENTOPTIONS
IN CGVHD (TABLE 4)
Prednisone (B III-1)
Corticosteroids have traditionally been the back-
bone of cGVHD therapy. Although the use of steroids
in first-line treatment is based on controlled trials,
their role in second-line therapy remains less clear be-
cause of a lack of data. In many studies on second-line
treatment of cGVHD drugs like MMF, sirolimus or
ECP were combined with continuous steroid adminis-
tration [18,23,27-30]. Thus, the contribution of
steroids to the reported response rates in these
studies remains uncertain. Because steroid-sparing is
an important goal in cGVHD patients, their dose is
usually reduced once symptoms of cGVHD are re-
solved and steroids may be stopped before dose reduc-
tion of other immunosuppressants. If cGVHD flares
during steroid taper, increasing the dose by 1 or 2 taper
steps may be enough to control symptoms. Consider-
ing the potential side effects of systemic steroids alone
and even more so in combination with other immuno-
suppressive agents, regular monitoring for osteoporo-
sis, arterial hypertension, and steroid induced diabetes
mellitus is recommended.Pulse of Steroids (C-2 III-2)
Currently, only 1 publication evaluated the efficacy
of high-dose corticosteroids. Akpek et al. [1] reported
Table 4. Second-line Treatment Options in cGVHD
Agent Recommendation Evidence Side Effects Comments
Steroids B III-1 osteoporosis, avascular necrosis, diabetes important but need to spare steroids because of
side effect profile
Photopheresis C-1 II venous access required spares steroids, excellent safety profile
mTOR inhibitors C-1 III-1 TAM, hyperlipidemia, hematotoxicity increased risk for TAM in combination with CNI,
lower efficacy in thrombocytopenia, requires
frequent monitoring
CNI C-1 III-1 renal toxicity, hypertension spares steroids, should be avoided in renal
impairment
MMF C-1 III-1 GI complaints, infectious and relapse risk increased risk for viral reactivation, spares
steroids, GI toxicity may mimic GVHD
clinically and histologically
Pentostatin C-2 II Hematotoxicity, infectious risk best results in children, caution in presence of
impaired marrow function, long-term
immunosuppression
MTX C-2 III-1 Hematotoxicity best response in mucocutaeous cGVHD, spares
steroids
Imatinib C-2 III-1 Fluid retention best results in sclerotic skin lesions, potentially
effective in mild and moderate BO
Rituximab C-2 II Infectious risk effective in auto-antibody mediated
manifestations as well as cutaneous and
musculosceletal cGVHD
Hydroxychloroquine C-2 III-2 GI complaints best results in mucocutaneous and liver
involvement
Clofazimine C-2 III-2 GI complaints, skin hyperpigmentation best results in mucocutaneous cGVHD
Thoracoabdominal irradiation C-2 III-2 Hematotoxicity best results in fasciitis or steroid dependent
mucocutaneous cGVHD, caution in presence
of impaired marrow function
Pulse of steroids C-2 III-2 Infectious risk rapid control of symptoms, identification of
steroid resistance
Thalidomide C-3 II Neurotoxicity, sedation, constipation may be used in concomitant relapse of MM
Azathioprine C-3 III-1 Hematotoxicity, infectious risk increased risk for oral malignancies
Retinoids C-3 III-2 Skin toxicity, Hyperlipidemia effective in sclerotic skin lesions
Alemtuzumab C-4 III-3 Infectious risk last resort
Alefacept C-4 III-3 Infectious risk last resort
Etanercept C-4 III-3 Infectious risk may be used in overlap syndrome with GI
manifestations
TAM indicates transplantation-associated microangiopathia; CIN, calcineurin inhibitor; cGVHD, chronic graft-versus-host disease; BO, bronchiolitis
obliterans.
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who were treated with methylprednisolone at 10 mg/
kg/day for 4 consecutive days followed by stepwise
dose reductions. After 4 days, all patients received
a course of additional immunosuppressive therapy.
Twenty-seven patients (48%) showed a major response
with substantial improvement of cGVHD manifesta-
tions, including softening of the skin, increased range
ofmotion, and improved performance status; 15 patients
(27%) showed a minor response, defined as improve-
ment in some but not all symptoms of cGVHD. The
treatment was well tolerated with no serious adverse
events. Although all patients received additional immu-
nosuppressive agents through their later course interfer-
ingwith the evaluationof the impactofhighdose steroids
on the extend of response, the results demonstrate that
high-dose methylprednisolone allows rapid clinical re-
sponse in patients with prior uncontrolled cGVHD, re-
quiring rapid control of symptoms. An additional
advantage of a pulse of high dose steroids is the immedi-
ate identification of steroid resistance especially in cuta-
neous manifestations of cGVHD.Calcineurin Inhibitors (C-1 III-1)
As in clinical practice, CNIs (either cyclosporine
[CsA] or tacrolimus) are frequently employed in
addition to corticosteroids as the initial treatment of
cGVHD, however, only limited experience exists on
their use as salvage therapy. In 2 small studies investi-
gating the effect of tacrolimus in patients with refrac-
tory cGvHD, overall response rates ranged between
35% and 46% [31,32]. In a study of 39 patients
receiving CsA already as part of their first-line treat-
ment, a change of CsA to tacrolimus offered some
benefit only in a small subset of patients [33].
In all, CNIs may represent a reasonable option
for patients with refractory or progressive cGVHD,
provided they have not been part of the first-line
therapeutic regimen or have shown prior therapeutic
activity. Moreover, a subset of patients may remain
CNIdependentby showing repeatedflares of symptoms
of cGVHD after withdrawal of CNI. Tacrolimus
clearance is age dependant in pediatric patients, and
especially children younger than 6 years of age have
6 Biol Blood Marrow Transplant 17:1-17, 2011D. Wolff et al.a higher clearance [34]. In contrast, a change from 1
CNI to another is unlikely to improve efficacy, but
may be justified for the presence of certain side effects
(eg, hyperlipidemia, hirsuitism, neurotoxicity). In gen-
eral, however, the toxicity profile of both available drugs
is usually overlapping (eg, nephrotoxicity, risk ofmicro-
angiopathy). If chosen, the mode of administration
and plasma trough level targets of both CNIs in
second-line treatment are usually similar to those em-
ployed in first-line treatment. Because long-term renal
toxicity is of concern, both substances may be applied
with plasma trough level targets at the lower therapeutic
limit.Extracorporeal Photopheresis (C-1 II)
During the last years a substantial number of pa-
tients have been treated with ECP for steroid-
dependent or steroid-refractory cGVHD [29,35-46].
The mechanisms of action are complex including
induction of apoptosis in all leukocyte subsets,
inhibition of proinflammatory cytokine production,
increase in anti-inflammatory cytokine production,
reduced stimulation of effector T cells, and induction
of donor-derived regulatory T cells (Tregs) [45,47].
Most of the clinical experience in ECP treatment of
steroid-refractory cGVHD patients is based on
retrospective analyses with a limited number of patients
[29,35-38,40,41,43,44,46-50] with consistently high
complete responses in up to 80% of patients with
cutaneous manifestations and significant improvement
in sclerodermatous skin involvement [29,46]. Couriel
et al. [38] reported in 71 patients with steroid-
refractory severe cGVHD a response rate of 61%,
with an inferior outcome in patients with thrombocyto-
penia and a trend toward a higher response rate in de
novo cGVHD. Kanold et al. [44] achived an overall re-
sponse rate of 63% in 63 children given ECP. Improve-
ment in visceral and lung manifestations of cGVHD to
ECP has been less consistent [29,35,37,38,40,43,46].
Two studies demonstrated, that earlier initiation of
ECP (\1 year) revealed better response rates in skin,
liver, and mucosal cGVHD [37,50]. The latter was not
confirmed by Foss et al. [40] and Apisarnthanarax et al.
[35]. So far, no treatment schedule (weekly versus 2
weekly) has reportedly revealed superior response rates.
However, because of the variety of ECP schedules, the
impact of dose intensity (number of cycles per month)
and length of treatment (number of cycles) cannot be as-
sessed accurately. Recently, Flowers et al. [28] reported
results of a prospective randomized phase II study in 95
patients with steroid-refractory/dependent/intolerant
cGVHD given ECP for 12 to 24 weeks in combination
with conventional immunosuppressants achieving no
significant difference in improvement of total skin score
(TSS) at week 12, but a significantly higher rate of com-
plete and partial responses of skin cGVHD as assessedby the nonblinded investigator in the ECP arm
compared to the control arm. In addition, significantly
more patients in the ECP arm had at least a 50%
reduction of steroid dose and at least a 25% decrease
of TSS at week 12. Of note, a steroid-sparing effect of
ECP has also been reported by other investigators
[29,38,40,43,49]. Significantly improved survival rates
and improvementsin quality of life have been reported
in ECP responders [28,29,50]. Therefore, ECP may
be a reasonable first choice in certain clinical scenarios
of steroid-refractory cGVHD. It requires a venous ac-
cess that may be difficult in patients with sclerotic skin
lesions and may occasionally require a central venous
line associated with increased risk for infections and
venous thrombosis.
Numerous investigators reported results on ECP
for treatment of cGVHD in children and adolescents
with high response rates in skin, liver, and oral mani-
festations of cGVHD and improved survival rates of
steroid-refractory patients [39,48-54].MMF (C-1 III-1)
Since the first publication of a case series with 26
patients at Johns Hopkins, MMF is increasingly used
in salvage therapy for refractory cGVHD [55,56].
Reported response rates in case series using different
definitions range between 40% and 75%, and no
randomized trial is available to prove the efficacy of
second-lineMMF in cGVHD alone or in combination
with other immunosuppressive drugs. Most of the
improvements have been observed in patients with
limited disease [30,57-62] and steroid sparing was
observed [59].
Nevertheless, some limitations for the use of MMF
as salvage therapy have to be considered such as side
effects, including gastrointestinal discomfort and diar-
rhea, which require dose reduction and may become
a reason for drug discontinuation. In addition, MMF
treatment can result in histopathologic changes of the
gut mucosa, which may mimic intestinal GVHD [63].
Hematologic toxicity such as leukopenia and thrombo-
cytopenia were observed especially in combinationwith
herpes virus infections [64]. Grade II hematologic
toxicity was reported for 6 of 21 pediatric patients and
other reports showed an incidence of neutropenia or
thrombocytopenia up to 10% [58,60,62]. Infectious
complications were observed in several case series
ranging from 10% to 50%. Baudard et al. [58] reported
serious infectious complications such as aspergillosis,
septicemia, andCMV reactivation in 6 of 15 patients in-
cluding3deaths inpatients givenMMFeither as a single
agent or in combination. Krejci et al. [60,62] observed
multiple serious infections in 14 of 21 pediatric
patients, whereas others recently published serious
infections in only 3 of 23 adult patients, respectively.
Interestingly, in the latter study, 5 of 23 patients died
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mentioned in other studies [60]. One potential explana-
tion for the different rates of infectious complications
reported in association with MMF may be differences
in severity of cGVHD, differences in the intensity of
immunosuppression, as well as comorbidities and the
use of prophylactic antifungal drugs.
Both inprophylaxis studies aswell as the randomized
trial mentioned, it became evident, that the use ofMMF
potentially increases the relapse risk inmyelogenousma-
lignancies if used as part of a triple agent regimen [13].
The published data on MMF as second-line therapy
for cGVHD provide very little information in this re-
spect. Baudard et al. [58] reported on 2 relapses in 20 pa-
tients with both acute GVHD (aGVHD) and cGVHD,
and Furlong et al. [60] observed 2 relapses in 23 patients
treated for cGVHD, respectively.
Given the information available, MMF represents
a second-line treatment option. A patient’s risk of
relapse should be considered and may influence a deci-
sion to use MMF as part of a multiagent regimen.Inhibitors of the Mammalian Target
of Rapamycin (C-1 III-1)
Sirolimus and everolimus, inhibitors of the mam-
malian target of rapamycin (mTOR-I), combine im-
munosuppressive properties with antiproliferative
effects on fibroblasts and smooth muscle cells [65].
mTOR-I exert their action by forming a complex
with the mammalian target of rapamycin (mTOR).
The generation of this complex results in cell cycle
arrest in G1 via inhibition of DNA transcription,
DNA translation, and protein synthesis. In contrast
to CNIs, sirolimus may promote the generation of
regulatory T cells [66]. The mTOR-I sirolimus and
everolimus have been extensively studied as immuno-
suppressants in solid organ transplantation. Substitut-
ing CNIs by mTOR-I seems to overcome long-term
threats, like chronic allograft dysfunction and vascul-
opathy as well as secondary skin cancer after solid
organ transplantation [67].
Considerable toxicity like TAM has been observed
when mTOR-I were used in combination with CNIs,
which could be avoided in a CNI-free regimen [68]. Si-
rolimus has also been evaluated in second-line treatment
of cGVHDin small phase II trialsmostly in combination
with CNIs achieving response rates between 56% and
81% [18,23,25,69]. Major adverse events observed
were hyperlipidemia, renal dysfunction, cytopenias,
and TAM, which lead to termination of therapy in up
to one-third of treated patients. A CNI free treatment
with mTOR-I in sclerodermatous manifestations of
cGVHD resulted in a similar response rate of 76% and
a low toxicity profile regarding nephropathy and TAM,
which correlated with high trough levels of mTOR-I
[70]. Importantly, no increased relapse rate has beenobserved, suggesting that the graft-versus-leukemia ef-
fect isnotcompromisedbymTOR-I therapy [71].Similar
results were reported on use of everolimus in combina-
tion with steroids and in part with azathioprine [72].
Because mTOR-I possibly interfere with wound
healing, they should be used with caution in patients
with cutaneous or mucosal ulcers [73]. Hyperlipidemia
is frequent, requires monitoring, and therapeutic inter-
vention with drugs not interfering with the mTOR-I
metabolism. In view of the reported side of effects of
mTOR-I including TAM when combined with
CNIs, cytopenias, and numerous interactions with
drugs frequently used in patients with cGVHD (mac-
rolides, antifungal azoles), close monitoring of blood
counts, trough levels, and serum chemistry is advisable.
In contrast to policy in prophylactic GVHD settings,
a loading dose ofmTOR-I should be avoided in salvage
therapy of cGVHD patients, and initial dosing should
be rather low in view of the long half-life of mTOR
inhibitors (eg, 0.25-0.5 mg/day). In patients receiving
concomitant voriconazole, the starting dose of siroli-
mus should be reduced by 90% (0.1 mg/day) [74].
Taken together, the mTOR-I sirolimus and
everolimus appear to be an effective treatment option
for cGVHD with an acceptable toxicity profile as
long as low therapeutic drug trough levels are main-
tained (4-8 ng/mL) and combination treatment with
CNIs is avoided.Thalidomide (C-3 II)
Although first-line treatment of cGVHD with
thalidomide in combination with CsA and prednisone
failed to result in improved response rates, thalidomide
showed a therapeutic activity in second-line treatment
of cGVHD[11].Themechanisms of action are complex
including inhibition of angiogenesis, expression of
adhesion molecules, several cytokines (tumor necrosis
factor [TNF]-alpha, interleukin [IL]6, IL12), andblock-
ade of NF-kappaB activity [75,76]. Initially, Vogelsang
et al. [77] reported results on treatment with thalido-
mide in 23 patients with refractory cGVHD and 21
patients with high-risk cGVHD. A complete response
was observed in 14 patients, a partial in 12, and no
response in 18 with acceptable toxicity consisting of
sedation, constipation and neuropathy. These findings
were confirmed by Browne et al. [78] reporting results
on 37 patients with refractory extensive cGVHD given
adjunct thalidomide with standard immunosuppressive
therapy. Fourteen of 37 patients (38%) responded to
thalidomide (1 complete, 13 partial) including 10 of 21
children (46%) and 4 of 16 adults (25%), respectively.
Parker at al. [79] reported a response rate of 20% in 80
patients given thalidomide with better results in stan-
dard risk cGVHD and combined oral and skinmanifes-
tations (40%). Kulkarni et al. [80] observed comparable
results in a cohort of 59 patients with a higher response
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[81] achieving a response rate of (40%) in this popula-
tion. The use of thalidomide is associated with signifi-
cant adverse effects consisting of constipation and
sleepiness in virtually all patients, neuropathy, skin ery-
thema, neutropenia, and thrombocytopenia. Moreover,
thalidomide requires anticoagulation because of an in-
creased risk of venous thrombosis [12]. An unexplained
feature remains the broad dose range tolerated through-
out the trials on thalidomide ranging from 150 mg to
1600mg/day. In summary, thalidomide remains a thera-
peutic option in second-line treatment of cGVHD, es-
pecially in mucocutaneous manifestations. The initial
dose should be 100 mg given at night with subsequent
dose escalation up to 400 mg/day. Thalidomide may
be given with split doses with 3 to 4 doses per day.
Hydroxychloroquine (C-2 III-2)
Hydroxychloroquine is a 4-aminoquinoline anti-
malarial drug that displays therapeutic activity in
a variety of autoimmune-mediated disorders, in partic-
ular, involving the mucocutaneous organ system.
Moreover, hydroxychloroquine is associated with
a steroid-sparing activity. Because of its ability to inter-
ferewith antigen processing and presentation, cytokine
production, and cytotoxicity, as well as its synergistic
immunosuppressive effects with CNIs in vitro, it was
evaluated in a phase II trial in 40 patients with
steroid-resistant or steroid-dependent cGVHD in
combination with different immunosuppressive agents
at 12 mg/kg (800 mg) per day [82]. Three complete
responses and 14 partial responseswere seen after ame-
dian of 8 (range: 4-24) weeks in 32 evaluable patients
(53% response rate) including 20 children. All re-
sponders tolerated a .50% reduction in their steroid
dose while receiving hydroxychloroquine. The highest
response rates were observed in skin, oral, and liver
manifestations, whereas efficacy in treatment of gastro-
intestinal manifestations was limited. Potential side
effects of hydroxychloroquine are gastrointestinal
symptoms like nausea, diarrhea, visual impairment
because of retinal toxicity when given for .2 years,
and neuropathy in patients with coexisting renal
insufficiency [83]. Of note is the need for dose reduc-
tion in the presence of cholestasis [84,85]. The
suggested dose of hydroxychloroquine (Quensyl) is
800 mg/day (12 mg/kg/day) given orally in 2 fractions
of 400 mg. A potential indication for the use of
hydroxychloroquine may be steroid dependent skin
or oral disease.
Azathioprine (C-3 III-1)
Azathioprine has been applied in treatment of
cGVHD including topical treatment of oral
manifestations [86,87]. In a double-blinded random-
ized trial in standard-risk cGVHD (platelets .100 109/L) patients, a significantly increased nonrelapse
mortality (NRM) rate (40% versus 21%) and a signifi-
cantly decreased overall survival (OS) (47% versus
61%) were observed in the combination arm of azathi-
oprine 1 prednisone compared to prednisone 1
placebo [87]. Although the study was performed 25
years ago and supportive care since that time has im-
proved considerably, the increased rate of oral malig-
nancies, observed in association with azathioprine
has to be of concern [88]. No standardized system
for analysis of thiopurine S-methyltransferase gene
polymorphism and the related thiopurine methyl
transferase activity is available for hematopoietic do-
nor chimera, and prospective typing may require the
genetic analysis of the donor and recipient to predict
the risk for toxic side effects related to azathioprine.Etretinate (C-3 III-2)/Isotretinoin (C-3 III-3)
Retinoids are known to interfere with collagen syn-
thesis in fibroblasts [89,90], promote the induction of
regulatory T cells, and block the induction of Th17
cells [91,92]. Based on reports of the successful use of
retinoids in systemic sclerosis, the efficacy of etretinate
(a synthetic retinoid) was retrospectively evaluated in
32 patients with refractory sclerodermatous cGVHD
byMarcellus et al. [19]. Etretinate was given in addition
to standard immunosuppression within a dose escala-
tion schedule starting with 0.25 mg/kg/day divided
into 4 doses. Twenty of 27 evaluable patients showed
improvement, including softening of the skin, flattening
of cutaneous lesions, increased range ofmotion, and im-
proved performance status. Four showed no response,
and 3 had progression of their sclerosis. Overall, etreti-
nate was well tolerated; however, skin breakdown and/
or ulceration led to treatment discontinuation in 6 pa-
tients.Other frequent side effects are hyperlipidemia re-
quiring monitoring of blood lipids, increase of
transaminases requiring monitoring of liver function
tests and teratogenicity. Because etretinate is no longer
available in Germany, its active metabolites acitretin
or isotretinoin may be suitable alternatives. Ghoreschi
et al. [93] reported 5 patients receiving isotretinoin at
a dose of 10mg/day in combinationwithPUVAand ob-
served a high response rate in sclerodermoid cGVHD.
Isotretinoin has been shown to be active in systemic
sclerosis, which shares common featureswith scleroder-
moid cGVHD [94-96]. Isotretinoin is typically applied
at 0.5 mg/kg/day in 2 fractions, and its cumulative
dose should be limited to 120 mg/kg equaling 6 to 8
months of treatment. So far, reports on the efficacy of
acitretin (Neotigason) are lacking, but the close
chemical relationship to its prodrug etretinate
including comparable side effects suggest activity also
in sclerodermoid manifestations of cGVHD. Acitretin
may be given orally with an initial dose of 2  10 mg
and subsequent dose escalation up to 30 mg/day.
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Polyclonal animal antihuman-lymphocyte anti-
bodies have successfully been used for decades to
prevent severe aGVHD and cGVHD after allogeneic
HSCT. In addition, several reports on its activity in
steroid-refractory aGVHD have been published.
However, currently there is no evidence for safe and
efficacious use of ATG/ALG as second-line treatment
of cGVHD.MONOCLONAL ANTIBODIES TARGETING T
CELLS (BASILIXIMAB, DACLIZUMAB, OKT3,
VISILIZUMAB)
For the directly T cell targeting agents Visilizu-
mab and OKT3 no evidence for their clinical activity
in refractory cGVHD is available in the literature. In
addition, reported data on anti-IL2-receptor anti-
bodies basiliximab and daclizumab do not allow any
recommendation for their use in refractory cGVHD
[97,98].CD52 Antibody Alemtuzumab (C-4 III-3)
Alemtuzumab is an unconjugated humanized IgG1
monoclonal antibody that depletes T, B, and NK cells,
and has also demonstrated activity on dendritic cells
[99,100]. Alemtuzumab is licensed for treatment of B
cell chronic lymphocytic leukemia and is the
treatment of choice in T cell prolymphocytic leukemia
[101]. Alemtuzumab (previously known as Campath-
1H) as part of the conditioning regimen reduces the
incidence of aGVHD and cGVHD, but may lead to
higher risk of relapse and infection [101-103]. The use
of alemtuzumab in cGVHD is very limited. Ruiz-
Arguelles et al. [104] report a cGVHD patient with
severe ulcerative colitis refractory to a variety of immu-
nosuppressants who recovered completely 7 months
after start of alemtuzumab initially given 10 mg for 6
days followed by monthly administration. Because sev-
eral groups observed response of aGVHD to signifi-
cantly lower doses of alemtuzumab, and infectious
morbidity and mortality correlate with the cumulative
dose of the drug, doses of 3 to 10mg every 14 days anal-
ogous to the experience in aGVHDmay also be consid-
ered in cGVHD patients [105,106]. The subcutaneous
application is much better tolerated than the
intravenous infusion, which requires premedication.
A pronounced suppression of the immune system
leading toopportunistic infections such asCMV, adeno-
virus, and toxoplasma is themost important side effect of
alemtuzumab [107,108]. Therefore, intense monitoring
for signs of infections, and adequate anti-infectious pro-
phylaxis are recommended. In patients with rheumatic
diseases, severe bone marrow failure was observed dur-
ing alemtuzumab therapy. In summary, further studiesare needed to assess the efficacy and safety of alemtuzu-
mab in treating cGVHD patients.Rituximab (C-2 II)
Based on recent findings about the involvement of
B cells in the pathogenesis of cGVHD therapeutic
strategies specifically targeting B cells have emerged
within the last years.
Rituximab is a monoclonal IgG1kappa chimeric
mouse/human anti-CD20 antibody, which has been
successfully used for treatment of large number of B
cell malignancies and autoimmune diseases. Rituxi-
mab binds to the extracellular part of the CD20 mol-
ecule and induces apoptosis as well as cellular and
complementmediated killing of normal and neoplastic
B cells.
Ratanatharathorn et al. [109] reported the first
patient with severe cGVHDand immune thrombocyto-
penia recovering completely after 4 doses of rituximab
at 375mg/m2.Thereafter, several case reports described
responses in patients with cGVHD-associated immune
phenomena like myasthenia gravis, bullous pemphi-
goid, or autoimmune haemolytic anemia [22,110,111].
Two small studies on 8 and 6 patients published in
2003 and 2004 reported organ-specific response rates
of 50% and 80%, mainly in patients with skin involve-
ment [112,113]. Cutler et al. [114] conducted the first
prospective phase I-II study reporting the efficacy of
rituximab (375 mg/m2) in 21 patients receiving a total
of 38 cycles. Objective responses were seen in 70% of
patients allowing a significant reduction of steroid
doses. In 2 patients (10%) with complete clinical
responses, all immunosuppressive therapy could be
discontinued. Patients with cutaneous or musculoskel-
etal manifestations of cGVHD had the highest proba-
bility to respond to rituximab. Antibody titers against
Y-chromosome encoded minor HLA-antigens de-
creased during the study period, whereas titers against
EBV and tetanus remained stable. Side effects included
mild infusion reactions and 9 CTC grade III-IV events
that were predominantly infectious episodes [114].
Following this prospective study a number of ret-
rospective studies were published covering more than
100 patients reporting good tolerability and a response
rate of 50% to 80%. In the majority, investigators used
the dose of 375 mg/m2 once a week for 4 to 8 infusions
[115-119].
Incontrast, vonBonin et al. [120], using substantially
lower doses of 50mg/m2/week for 4weeks in 11 patients
with steroid refractory cGVHD and 2 with posttrans-
plant autoimmune disorders (glomerulonephritis and
immune-thrombocytopenia), observed similar efficacy
with anoverall response rate of 69% including 3 patients
(23%) with complete remission (CR).
In view of the reported activity and toxicity profile,
rituximab can be recommended as a reasonable
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rodermatous, lichenoid cutaneous disease, as well as
in autoantibody-mediated cytopenias [21]. The active
dose is still a matter of debate and should be further
investigated in prospective studies.Alefacept (C-4 III-3)
Alefacept is a dimeric Anti-CD2 LFA-3 fusion
protein used for the treatment of psoriasis, and has
been applied in the treatment of aGVHDand cGVHD
[121-123]. Shapira et al. [121] reported 12 patients
with cGVHD resistant to at least 2 lines of standard
therapy who received alefacept at 30 mg once per
week for a median of 8 (range: 1-25) weeks. Nine of
11 evaluable patients showed some response, which
was marked in 3, moderate in 2, and minimal in 4.
Six patients died because of GVHD progression and
associated infections. Definitely, more studies are
needed before alefacept can be generally recommen-
ded as a safe second-line treatment for cGVHD.Etanercept (C-4 III-3) and Infliximab (C-4 III-3)
Data on the use of infliximab and etanercept for
treatment of steroid-refractory cGVHD are limited
to\10 patients for infliximab and\20 patients for eta-
nercept [124-126]. Infliximab is a chimeric human
anti-TNF-a-IgG1k monoclonal antibody, which
binds with high affinity to the soluble and
transmembrane forms of TNF-a, hereby blocking
their interactions with their cellular receptors and
causing lysis of cells that produce TNF-a [127,128].
Etanercept is a fusion protein consisting of 2
identical chains of the human TNF-receptor p75
monomer fused with the Fc domain of human IgG1.
Unlike infliximab, it does not eliminate TNF-
positive cells via antibody-dependent cytotoxicity
(ADCC) and induction of monocyte apoptosis. The
elimination of TNF-positive cells has been associated
with an increased rate of infectious mortality that ap-
plies to the use of infliximab. Busca et al. [124] reported
a series of 8 patients with cGVHD treated with etaner-
cept at 25 mg subcutaneously twice weekly for 4 weeks
followed by 25 mg weekly for 4 weeks. Overall, 5 of 8
patients (52%) responded to the treatment (CR: n5 1,
partial remission [PR]: n5 4) including 2 with gastro-
intestinal involvement. The results are in line with a re-
port by Chiang et al. [129], who treated 10 patients
with steroid-dependent cGVHD according to the
same schedule. Seven of 8 patients finishing the 8-
week treatment course without adverse side effects
showed improvement. Although etanercept should be
further investigated in cGVHD, it may be of use in se-
lected patients with gastrointestinal or cutaneous man-
ifestations of steroid-refractory cGVHD.Imatinib (C-2 III-1)
Imatinib, a multikinase inhibitor successfully
employed in BCR-ABL-positive malignancies, has
recently been proposed as adjunctive treatment in
cGVHD on the basis of its antifibrotic activity target-
ing the platelet-derived growth factor receptor
(PDGFR) and transforming growth factor beta
(TGF-b) pathways [130,131].
In 2006, Majhail et al. [132] reported a patient with
relapse of chronic myelogenous leukemia (CML) and
concurrent bronchiolitis obliterans (BO) after HSCT,
in whom imatinib at 400 mg daily not only resulted in
molecular remission but also in amelioration of
bronchiolitis. In 2008, Magro et al. [133] andMoreno-
Romero et al. [134] contributed cases of imatinib-
induced improvement of sclerodermatous cGVHD.
Recently, a small retrospective series (n 5 14) and 2
small prospective phase I-II studies (n 5 19 and n 5
9) on adjunct imatinib at 100 to 400 mg daily in refrac-
tory extensive cGVHD have been published [135-137].
Imatinib toxicity consisted of hematologic toxicity,
fluid retention, and dyspnea, and was mostly mild, but
precluded a dose increase and/or lead to drug
discontinuation in 15% to 25% of patients. Of note, 1
CML patient developed secondary lymphoma.
Responses to imatinib (about half partial, half
complete) occurred within 6 months in 50% to 80%
of patients with cutaneous, eye, and intestinal
cGVHD. In pulmonary cGVHD best results were
observed in mild BO, whereas in moderate and severe
pulmonary cGVHD, only minor improvements were
seen. Hence, imatinib seems to be safe and feasible
but further prospective studies are warranted to
confirm its role in therapy of cGVHD. Currently, an
initial dose of 100-200 mg imatinib is suggested, with
subsequent dose escalation up to 400 mg daily if
tolerated. No data on the benefit of other tyrosine
kinase inhibitors besides imatinib are currently
available.Pentostatin (C-2 II)
Pentostatin (deoxycoformicin; Nipent) is a nucle-
oside analog that irreversibly inhibits adenosine deam-
inase, an enzyme expressed in lymphocytes that
mediates recycling of purines [138,139]. Following
the successful use of pentostatin in steroid-refractory
aGVHD, and because of its low hematotoxic profile,
the compound was subsequently investigated in refrac-
tory cGVHD [140].
Jacobsohn et al. [17] performed a phase II study in
58 patients with intensively pretreated refractory
cGVHD given pentostatin at 4 mg/m2 every second
week for a median of 12 doses (range: 1-32 doses).
The overall response rate was 55%, with major re-
sponses in 31 patients and improvement of lichenoid
cutaneous manifestations in 69%. Toxicity was
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fect and severe infections grades III-IV in 20% of pa-
tients. Four patients discontinued therapy early.
Mortality of 33% was mainly because of cGVHD
with or without infection [17]. Encouraging results
were also observed in 5 children with steroid-
refractory cGVHDwith significant improvement of li-
chenoid and sclerodermatous skin involvement [15].
Oral GVHD resolved completely in 2 patients and
no severe infections were observed. Recently, a phase
II trial in 51 children with steroid-refractory cGVHD
has been published by the Pediatric Blood andMarrow
Transplant Consortium. Application of pentostatin re-
sulted in an overall response rate of 53%, including
a 59% response rate in sclerosis. In 25% of patients,
toxicity of the compound required discontinuation of
treatment [141].
The moderate toxicity profile and the favorable re-
sponse rate emphasize further evaluation of pentosta-
tin in adults and children with cGVHD [17,141].
Application of a 4 mg/m2 dose of pentostatin every
second week for 3 months is recommended. In case
of creatinine clearance \50 mL/min/1.73 m2, the
dose should be reduced by 50%; in case of clearance
\30 mL/min/1.73 m2, treatment should be
interrupted. The dose should be reduced by 25% if
grade III hematotoxicity occurs. Neutropenia,
thrombocytopenia \20  109/L, or fever require
dose reduction by 50%, whereas pentostatin should
be completely withheld in case of severe infection
[142]. As infections were reported as the most frequent
complication of pentostatin application in cGVHD,
the compound should not be given when severe immu-
nodeficiency because of recurrent infections is
assumed. Thus, pentostatin should not be used for
pulmonary cGVHD.Low-Dose Methotrexate (MTX) (C-2 III-1)
In view of the anti-inflammatory and antiprolifer-
ative properties and its successful use in patients with
autoimmune disorders, for example, rheumatoid ar-
thritis, several authors evaluated the use of low dose
methotrexate (MTX) for cGVHD in limited case se-
ries. Observations that low doses of MTX can induce
a sustained suppression of T cell activation and expres-
sion of adhesion molecules further support its use in
cGVHD therapy [143].
The MTX dosage varied from 5 to 10 mg/m2
weekly [144,145] to 5 to 10 mg/m2 every 3 or 4 days
in the different reports resulting in partial or
complete remissions of steroid-refractory or severe
cGVHD in .70% of adult patients [144,146,147].
Inagaki et al. [145] observed complete or partial remis-
sions in 50% of 17 pediatric patients with steroid-
refractory or steroid-dependent GVHD. Besides
high response rates steroid-sparing effects werereported and in most cases, response was seen already
after the first MTX dose [147].
Huang et al. [146] reported severe leukopenia
(white blood cell count [WBC]\2  109/L) in 14%
of patients with cGVHD that was reversible despite
continuation of MTX therapy and did not lead to
discontinuation of medication. Inagaki et al. [145]
observed grade III-IV hematotoxicity in 15% and grade
II hepatotoxicity in 7%, which improved after interrup-
tion of MTX. Mortality rates of 5% because of pul-
monary infections were reported [145,146]. In
general, all studies reported good tolerance of low-
doseMTX in adults as well as in childrenwithmoderate
toxicity including easily manageable hematotoxicity.
These results support further evaluation of adjunct
low-dose MTX as frontline therapy as reported by
Wang et al. [148] in 86 patients with cGVHD. Grade
III toxicity because of cytopenia or oral mucositis was
only observed in 3% of patients. The highest response
was seen in skin cGVHDwith improvement in 90% of
patients. Low-dose MTX does not seem to increase
the risk of relapse of the underlying disease in cGVHD
patients, and long-term use of weekly low-dose MTX
seems feasible [145].
In conclusion, the aforementioned studies suggest
that MTX is an option mainly for skin and oral mani-
festations of cGVHD. A dosage of 5 to 10 mg/m2
weekly might be recommended; in the case of intesti-
nal, involvement, intravenous (i.v.) application might
be more suitable [144]. In the case of leukopenia
\2  109/L or thrombocytopenia \50  109/L,
dose reduction to 5 mg/m2 seems to be more appropri-
ate. In the case of renal insufficiency, dose reduction is
also recommended. Because of the hepatotoxicity of
the compound, hepatitis-like cGVHD seems to be
a contraindication. Caution is advised in patients
with preexisting renal insufficiency, pancytopenia, or
recurring infections. Folate support should be per-
formed in accordance with the experience of other in-
vestigators usingMTXover long periods of time [149].Cyclophosphamide (C-4 III-3)
Cyclophosphamide (Cy) is an established immu-
nosuppressive and cytotoxic drug widely used as part
of pretransplant conditioning regimens. In a few
reports, high-dose Cy (200 mg/kg) followed by ‘‘pseu-
doautologous’’ stem cell rescue was applied in
refractory cGVHD patients resulting in resolution of
cGVHD, but also relapse of the underlying
hematological malignancy [150].
Mayer et al. [151] evaluated pulsed treatment with
Cy at a median of 1000 mg/m2 in addition to steroids
and MMF in 15 patients with steroid-refractory
aGVHD or cGVHD (n 5 3), resulting in complete
resolution of liver GVHD in 2 patients and in partial
remission of oral cavity GvHD in 1 case. Infectious
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seen in 1 patient each [151].
Therefore, further evaluation of Cy in cGVHD
appears justified. Hematopoietic impairment and
a history of recurrent infections seem to represent con-
traindications and comedication with mesna (Uromi-
texan) is recommended. The pulse schedule of Cy
differs from doses used in patients with, for example,
scleroderma, where long-term application of oral daily
dose of #2 mg/kg body weight has been successfully
applied [152]. Also, for other autoimmune disorders
such as BOOP, lupus nephritis, or autoimmune vascu-
litis, Cy has been successfully used [153-155].
According to the consensus conference, it is diffi-
cult to draw any conclusions on use of CY in patients
with cGVHD because the literature is very limited.
Clofazimine (C-2 III-2)
Clofazimine (Lamprene) is an antimycobacterial
drug that has anti-inflammatory activity and is thought
to reflect functional inhibition of pathogenic T lym-
phocytes in various autoimmune skin disorders such
as cutaneous lupus erythematodes, and has been exten-
sively used for treatment of leprosy andMycobacterium
avium complex since the 1960s [156].
Based on its tissue distribution with secretion in
sweat, tears, or skin, and its apparent immunomodula-
tory properties, this compound was explored in
cGVHD. Lee et al. [156] reported 22 patients with
cGVHD given 300 mg orally in a single daily dose
for 90 days followed by dose reduction to 100mg daily.
Treatment lasted 7 to 835 days and was generally well
tolerated besides mild gastrointestinal toxicity in 36%
of patients or reddish-brown hyperpigmentation of the
skin. Partial responses only were achieved in 55% of
patients both with limited as well as extensive
cGVHD. In 23% of patients, other immunosuppres-
sive drugs could be reduced. The compound seemed
most effective in skin, joint, or oral involvement. An-
other report fromRzepecki et al. [157] documented ex-
perience with clofazimine in 4 patients with cGVHD,
who all achieved PR or CR of symptoms with good
tolerance of the compound. One pediatric patient
with cGVHD was reported to have an episode of met-
hemoglobinemia under treatment with clofazimine
that could be managed with methylene blue and ascor-
bic acid. However, it seems that this potentially dan-
gerous adverse reaction is because of the known
hemoglobin-oxidation potential of clofazimine [158].
Low-Dose Thoracoabdominal Irradiation
(C-2 III-2)
The well-known immunosuppressive and immuno-
modulatory capacity of irradiation has been investigated
by Robin et al. [16] in a retrospective analysis of low-
dose thoracoabdominal irradiation (1 Gy) in 41 pa-
tients with refractory extensive cGVHD. Of note wasa high response rate of 82% with best responses ob-
served in fasciitis (79%) and oral GVHD lesions
(73%). Two years after thoracoabdominal irradiation,
a CR was achieved in 11 patients. Fifty-seven percent
of patients had an at least 50% reduction of their cor-
ticosteroid dose by 6 months after treatment. Two-
year cGVHD relapse incidence was 34% and patients
with fasciitis, lymphocytes.1.0 109/L, and platelets
.200  109/L had a better outcome. Side effects were
a mild transient pancytopenia with a late nadir approx-
imately 3 weeks after treatment. The high response
rate was confirmed by Bullorsky et al. [159], demon-
strating an improvement in 3 patients with cGVHD.
In summary, low-dose thoracoabdominal irradiation
is a safe and efficient option in patients with refractory
cGVHD, allowing a significant tapering of systemic
corticosteroids in most cases.RESULTS OF THE SURVEY
Thirty of 37 transplant centers performing allo-
HSCT within Germany (n 5 34), Austria (n 5 3),
and Switzerland (n 5 1) responded to the paper-
based survey on second-line treatment sent via e-mail
to representatives of the centers. One center re-
sponded only to specific question but did not report
on the frequency of applied agents and was therefore
excluded from the analysis presented in Table 1.
The first question involved a patient with de novo
cGVHD of skin, oral mucosa, eyes, and liver 5 months
after myeloablative conditioning for an allogeneic-
related HSCT for AML in first CR not responding
to initial treatment with prednisone at 1 mg/kg/day
and asked about the first choice of an additional immu-
nosuppressive agent. Two centers each (7%) preferred
adding either MMF, tacrolimus, or pulse of steroids,
whereas 11 centers (37%) mentioned CsA. One center
(3%) preferred an mTOR inhibitor and 4 (13%) ECP.
Several centers suggested using a triple agent combi-
nation consisting of CsA, a pulse of steroids, and
ECP (n 5 1), steroids, MMF, and CsA (n 5 1), CsA
or tacrolimus combined with MTX or sirolimus and
ECP (n 5 1), and steroids, CsA, and ECP (n 5 3).
One center suggested adding 3 agents consisting of
CsA, ECP, and rituximab (n 5 1).
Second, centers were asked whether mTOR inhib-
itors are combined with CNI in second-line treatment
of cGVHD. Seventeen centers (57%) stated avoiding
this combination completely, 7 each use either everoli-
mus or sirolimus combined with tacrolimus, 5 each
combine either everolimus or sirolimus with CsA.
The third question concerned a patient after allo-
HSCT for standard-risk acute myelogenous leukemia
(AML) in first CR with moderate cGVHD with skin,
oral mucosa, and liver, involvement responding com-
pletely to first-line treatment with prednisone and
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moderate oral involvement.
Twenty-eight centers (93%) stated not to change
systemic immunosuppression but to add topical bude-
sonide (n5 8), tacrolimus (n5 11), topical steroids not
specified (n 5 10), or topical dexamethasone (n 5 3).
Five other centers would add topical CsA. Three cen-
ters preferred a change of systemic immunosuppres-
sion adding MMF (n 5 1), or ECP (n 5 2) in
combination with additional topical treatment with ei-
ther tacrolimus (n5 1) or topical steroids (n5 2). Only
1 center reported not using topical immunosuppres-
sion and to start everolimus to improve oral cGVHD.
(Several centers reported more than 1 approach.)CONCLUSIONS
The continuing significant morbidity and mortal-
ity of cGVHD seen especially in patients with severe
disease manifestations remains a therapeutic challenge
[160]. Although a number of immunosuppressive
agents have demonstrated therapeutic activity in
cGVHD, most of these treatment options have not
been investigated systematically. Moreover, evidence
is sparse and limited to phase II trials or small case se-
ries with inhomogenous inclusion criteria, lack of doc-
umentation of severity of cGVHD, and insufficient
response assessment.
To improve this situation, the Consensus confer-
ence on clinical practice in cGVHD proposed several
goals to be achieved through the next decade for im-
provement of patient outcome. First of all, the cur-
rently available most frequently used treatment
strategies should be evaluated in a controlled manner
applying the NIH consensus criteria [5-9].
Because it will be difficult to assess the efficacy of
the majority of substances in formal phase II/III trials,
additional observational studies may provide useful in-
formation on their efficacy, but they do not replace the
need for formal trials. In this context the Consensus
conference on clinical practice in cGVHD achieved
an agreement on the use of diagnostic criteria, severity
staging, as well as response assessment of cGVHD in
daily clinical routine as a prerequisite for performing
observational studies within this clinical network of
transplant facilities (Greinix et al., BBMT, submitted).
A second aim is to develop valid predictors of
response to replace the ‘‘trial-and-error system’’ by
an individualized approach taking into account the
pathophysiologic heterogeneity of cGVHD. Thus,
potential biomarkers including cytokines, proteomic
patterns, and cellular subpopulations can be investi-
gated within the Consensus consortium correlating
laboratory parameters with observed responses ac-
cording to the NIH staging and response assessment
criteria. A third aim for improvement of patientoutcome is defining more efficacious and safe treat-
ment options for specified organ manifestations early
in the course of cGVHD in clinical phase I/II trials
to avoid development of irreversible organ damage
and long-lasting immunodeficiency leading to severe
infectious complications.ACKNOWLEDGMENTS
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